# William Anderson

#### List of Publications by Citations

Source: https://exaly.com/author-pdf/1201411/william-anderson-publications-by-citations.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

2,881 105 50 32 h-index g-index citations papers 6.9 4.82 111 3,532 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
105	Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. <i>Blood</i> , <b>2005</b> , 105, 2510-8	2.2	146
104	Osteogenesis imperfecta is linked to both type I collagen structural genes. <i>Lancet, The</i> , <b>1986</b> , 2, 69-72	40	144
103	Genes, chromosomes, and rhabdomyosarcoma. <i>Genes Chromosomes and Cancer</i> , <b>1999</b> , 26, 275-285	5	129
102	T cells for cancer immunotherapy: A systematic review of clinical trials. <i>OncoImmunology</i> , <b>2014</b> , 3, e27572	7.2	124
101	A molecular map of mesenchymal tumors. <i>Genome Biology</i> , <b>2005</b> , 6, R76	18.3	104
100	Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation. <i>Molecular Therapy</i> , <b>2018</b> , 26, 354-365	11.7	102
99	New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5814-21	12.9	98
98	Human IT lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. <i>Journal of Immunology</i> , <b>2012</b> , 188, 1708-16	5.3	95
97	Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 880-8	2.2	95
96	Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 663-77	9.7	71
95	Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. <i>Neoplasia</i> , <b>1999</b> , 1, 340-8	6.4	67
94	Cytogenetic abnormalities in 42 rhabdomyosarcoma: a United Kingdom Cancer Cytogenetics Group Study. <i>Medical and Pediatric Oncology</i> , <b>2001</b> , 36, 259-67		62
93	A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma <b>2000</b> , 28, 220-2	26	62
92	PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. <i>American Journal of Pathology</i> , <b>2001</b> , 159, 1089-96	5.8	61
91	Neuroblastoma killing properties of VI and VI-negative II cells following expansion by artificial antigen-presenting cells. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5720-32	12.9	59
90	Polyphenon [corrected] E enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 1116-25	12.9	58
89	Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity. <i>Cancer Research</i> , <b>2015</b> , 75, 3043-53	10.1	54

## (2003-2010)

88	Clinical and pathological features of paediatric malignant rhabdoid tumours. <i>Pediatric Blood and Cancer</i> , <b>2010</b> , 54, 29-34	3	53	
87	Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. <i>Nature Communications</i> , <b>2018</b> , 9, 2378	17.4	50	
86	Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor. <i>Molecular Therapy</i> , <b>2017</b> , 25, 1234-1247	11.7	48	
85	Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein. <i>Journal of Experimental Medicine</i> , <b>2005</b> , 202, 1399-410	16.6	48	
84	Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma. <i>Clinical and Translational Oncology</i> , <b>2012</b> , 14, 271-9	3.6	47	
83	Identification of new Wilms tumour predisposition genes: an exome sequencing study. <i>The Lancet Child and Adolescent Health</i> , <b>2019</b> , 3, 322-331	14.5	46	
82	Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1409	8.4	42	
81	Novel formation and amplification of the PAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma. <i>Genes Chromosomes and Cancer</i> , <b>1996</b> , 17, 7-13	5	41	
80	Embryonal precursors of Wilms tumor. <i>Science</i> , <b>2019</b> , 366, 1247-1251	33.3	40	
79	Response without shrinkage in bilateral Wilms tumor: significance of rhabdomyomatous histology. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2002</b> , 24, 31-4	1.2	38	
78	Patterns of shift in ADC distributions in abdominal tumours during chemotherapy-feasibility study. <i>Pediatric Radiology</i> , <b>2011</b> , 41, 99-106	2.8	37	
77	Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	37	
76	The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. <i>Growth Factors</i> , <b>2006</b> , 24, 197-208	1.6	36	
75	An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers. <i>PLoS ONE</i> , <b>2016</b> , 11, e0152196	3.7	36	
74	Pilot study of F(18)-Fluorodeoxyglucose Positron Emission Tomography/computerised tomography in Wilms' tumour: correlation with conventional imaging, pathology and immunohistochemistry. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 389-96	7·5	33	
73	The Brn-3b transcription factor regulates the growth, behavior, and invasiveness of human neuroblastoma cells in vitro and in vivo. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 21617-27	5.4	32	
72	Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. <i>Nature Communications</i> , <b>2020</b> , 11, 4324	17.4	32	
71	Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case. <i>Cancer Genetics and Cytogenetics</i> , <b>2003</b> , 140, 73-7		30	

70	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. <i>European Journal of Cancer</i> , <b>2020</b> , 127, 52-66	7.5	26
69	Rhabdomyosarcoma subtyping by immunohistochemical assessment of myogenin: tissue array study and review of the literature. <i>Pathology and Oncology Research</i> , <b>2008</b> , 14, 233-8	2.6	25
68	Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell. <i>Science Advances</i> , <b>2021</b> , 7,	14.3	23
67	A pathogenic mosaic TP53 mutation in two germ layers detected by next generation sequencing. <i>PLoS ONE</i> , <b>2014</b> , 9, e96531	3.7	22
66	Post-thaw viability of cryopreserved peripheral blood stem cells (PBSC) does not guarantee functional activity: important implications for quality assurance of stem cell transplant programmes. <i>British Journal of Haematology</i> , <b>2016</b> , 174, 942-51	4.5	22
65	A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. <i>European Journal of Cancer</i> , <b>2019</b> , 121, 224-235	7.5	21
64	Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine. <i>Cancer Immunology, Immunotherapy</i> , <b>2011</b> , 60, 1243-55	7.4	21
63	PAX5 expression in nonhematopoietic tissues. Reappraisal of previous studies. <i>American Journal of Clinical Pathology</i> , <b>2010</b> , 133, 407-15	1.9	21
62	Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis. <i>Cancer Research</i> , <b>2019</b> , 79, 5382-5393	10.1	21
61	Bone marrow-derived IFN-producing killer dendritic cells account for the tumoricidal activity of unpulsed dendritic cells. <i>Journal of Immunology</i> , <b>2008</b> , 181, 6654-63	5.3	19
60	Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with V♥V♥+ ■ cells. <i>OncoImmunology</i> , <b>2016</b> , 5, e1025194	7.2	18
59	Persistent complete response after single-agent sunitinib treatment in a case of TFE translocation positive relapsed metastatic pediatric renal cell carcinoma. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2013</b> , 35, e1-3	1.2	18
58	MYCN as a target for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , <b>2008</b> , 57, 693-700	7.4	18
57	Ultrasound-guided core needle biopsy for the diagnosis of rhabdomyosarcoma in childhood. <i>Pediatric Blood and Cancer</i> , <b>2009</b> , 53, 356-60	3	16
56	Development of cellular immune responses against PAX5, a novel target for cancer immunotherapy. <i>Cancer Research</i> , <b>2008</b> , 68, 8058-65	10.1	15
55	Migratory and antigen presentation functions of IFN-producing killer dendritic cells. <i>Cancer Research</i> , <b>2009</b> , 69, 6598-606	10.1	14
54	MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma. <i>Expert Review of Anticancer Therapy</i> , <b>2006</b> , 6, 217-24	3.5	14
53	The immune environment of paediatric solid malignancies: evidence from an immunohistochemical study of clinical cases. <i>Fetal and Pediatric Pathology</i> , <b>2013</b> , 32, 298-307	1.7	13

## (2007-2010)

52	A novel small-molecule inhibitor of IL-6 signalling. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2010</b> , 20, 7029-32	2.9	12
51	Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015. <i>Human Gene Therapy</i> , <b>2015</b> , 26, 276-85	4.8	11
50	Licensing of <b>I</b> cells for professional antigen presentation: A new role for antibodies in regulation of antitumor immune responses. <i>OncoImmunology</i> , <b>2012</b> , 1, 1652-1654	7.2	11
49	Engineering <b>II</b> cells limits tonic signaling associated with chimeric antigen receptors. <i>Science Signaling</i> , <b>2019</b> , 12,	8.8	10
48	Development of anti-PAX3 immune responses; a target for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , <b>2007</b> , 56, 1381-95	7.4	10
47	Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 161, 103325	7	10
46	Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy. <i>Oncolmmunology</i> , <b>2015</b> , 4, e973808	7.2	9
45	Lineage-Independent Tumors in Bilateral Neuroblastoma. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1860-1865	59.2	9
44	Noninvasive MRI Native T Mapping Detects Response to -targeted Therapies in the Th- Model of Neuroblastoma. <i>Cancer Research</i> , <b>2020</b> , 80, 3424-3435	10.1	9
43	Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function. <i>PLoS ONE</i> , <b>2019</b> , 14, e0216373	3.7	9
42	Engineered human mesenchymal stem cells for neuroblastoma therapeutics. <i>Oncology Reports</i> , <b>2019</b> , 42, 35-42	3.5	9
41	STAT3 Regulates Proliferation and Immunogenicity of the Ewing Family of Tumors In Vitro. <i>Sarcoma</i> , <b>2012</b> , 2012, 987239	3.1	9
40	PAX5 expression in rhabdomyosarcoma. American Journal of Surgical Pathology, 2009, 33, 1575-7	6.7	9
39	Uneventful administration of vincristine in Charcot-Marie-Tooth disease type 1X. <i>Pediatric Blood and Cancer</i> , <b>2008</b> , 50, 874-6	3	9
38	MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment. <i>Cancer Research</i> , <b>2019</b> , 79, 2978-2991	10.1	8
37	Distant metastatic spread of molecularly proven infantile fibrosarcoma of the chest in a 2-month-old girl: case report and review of literature. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2014</b> , 36, 231-3	1.2	8
36	Characterisation and validation of insertions and deletions in 173 patient exomes. <i>PLoS ONE</i> , <b>2012</b> , 7, e51292	3.7	8
35	B-MYB is hypophosphorylated and resistant to degradation in neuroblastoma: implications for cell survival. <i>Blood Cells, Molecules, and Diseases</i> , <b>2007</b> , 39, 263-71	2.1	8

34	Establishment and phenotyping of neurosphere cultures from primary neuroblastoma samples. <i>F1000Research</i> , <b>2019</b> , 8, 823	3.6	8
33	Congenital malignant rhabdoid tumor of the scalp. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , <b>2012</b> , 40, e258-60	3.6	7
32	Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR. <i>Pediatric Blood and Cancer</i> , <b>2006</b> , 46, 820-4	3	7
31	Inflammation: what role in pediatric cancer?. <i>Pediatric Blood and Cancer</i> , <b>2012</b> , 58, 659-64	3	6
30	Catechins and antitumor immunity: Not MDSC's cup of tea. <i>Oncolmmunology</i> , <b>2013</b> , 2, e24443	7.2	6
29	A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3398-409	12.9	6
28	Unleashing the immune response against childhood solid cancers. <i>Pediatric Blood and Cancer</i> , <b>2017</b> , 64, e26548	3	5
27	Licensing of killer dendritic cells in mouse and humans: functional similarities between IKDC and human blood IT-lymphocytes. <i>Journal of Immunotoxicology</i> , <b>2012</b> , 9, 259-66	3.1	5
26	Immunohistochemical nuclear positivity for WT1 in childhood acute myeloid leukemia. <i>Fetal and Pediatric Pathology</i> , <b>2007</b> , 26, 193-7	1.7	5
25	Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment. <i>Blood</i> , <b>2021</b> , 137, 2992-2997	2.2	5
24	Fluorescence imaging in pediatric surgery: State-of-the-art and future perspectives. <i>Journal of Pediatric Surgery</i> , <b>2021</b> , 56, 655-662	2.6	5
23	Brain lipid-binding protein: a marker of differentiation in neuroblastic tumors. <i>Journal of Pediatric Surgery</i> , <b>2011</b> , 46, 1197-200	2.6	4
22	The RAC specific guanine nucleotide exchange factor Asef functions downstream from TEL-AML1 to promote leukaemic transformation. <i>Leukemia Research</i> , <b>2010</b> , 34, 109-15	2.7	4
21	The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma. <i>Human Pathology</i> , <b>2019</b> , 86, 182-192	3.7	4
20	Alcohol-abuse drug disulfiram targets pediatric glioma via MLL degradation. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 785	9.8	4
19	Regeneration of stalled immune responses to transformed and infected cells using <b>IT</b> cells. <i>Drug Discovery Today</i> , <b>2014</b> , 19, 787-793	8.8	3
18	Malignant rhabdoid tumors: a familial condition?. <i>Pediatric Blood and Cancer</i> , <b>2011</b> , 56, 1-2	3	3
17	Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours <i>European Journal of Cancer</i> , <b>2021</b> ,	7.5	3

#### LIST OF PUBLICATIONS

16	Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
15	Combined Effects of Myeloid Cells in the Neuroblastoma Tumor Microenvironment. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
14	Novel Treatments and Technologies Applied to the Cure of Neuroblastoma. <i>Children</i> , <b>2021</b> , 8,	2.8	3
13	Cytogenetic abnormalities in 42 rhabdomyosarcoma: A United Kingdom cancer cytogenetics group study <b>2001</b> , 36, 259		3
12	Soft Tissue Sarcoma <b>2010</b> , 216-233		2
11	Developing immunotherapies for childhood cancer. <i>Archives of Disease in Childhood: Education and Practice Edition</i> , <b>2017</b> , 102, 162-165	0.5	1
10	PAX3-FKHR chimeric oncoprotein: hiding itself from immune detection?. <i>Cell Cycle</i> , <b>2006</b> , 5, 563-4	4.7	1
9	Tumor-Associated Antigen Presentation by IT-Cells in Cancer Immunotherapy. <i>Blood</i> , <b>2014</b> , 124, 1411	-14 <u>1.1</u>	1
8	Long-term kidney function in children with Wilms tumour and constitutional WT1 pathogenic variant. <i>Pediatric Nephrology</i> , <b>2021</b> , 1	3.2	1
7	Antibody based therapy for childhood solid cancers. <i>Current Opinion in Chemical Engineering</i> , <b>2018</b> , 19, 153-162	5.4	O
6	Importance of Magnetic Resonance Imaging With Diffusion-weighted Imaging in Guiding Biopsy of Nodular Ganglioneuroblastoma: A Case Report. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2021</b> , 43, 6	13 <del>0-</del> e1	35 <sup>O</sup>
5	Augmenting human gamma delta lymphocytes for cancer therapy with chimeric antigen receptors. <i>Exploration of Immunology</i> ,168-179		O
4	Adoptive T Cell Therapies for Children Cancers <b>2018</b> , 161-174		
3	Flow cytometry of bone marrow aspirates from neuroblastoma patients is a highly sensitive technique for quantification of low-level neuroblastoma <i>F1000Research</i> , <b>2021</b> , 10, 947	3.6	
2	Flow cytometry of bone marrow aspirates from neuroblastoma patients is a highly sensitive technique for quantification of low-level neuroblastoma. <i>F1000Research</i> ,10, 947	3.6	
1	ATRT-20. Novel prognostic molecular signatures for improved risk-classification of Atypical Teratoid Rhabdoid Tumours. <i>Neuro-Oncology</i> , <b>2022</b> , 24, i7-i7	1	